No abstract

Introduction: Hepatitis B virus (HBV) and hepatitis C virus (HCV) represent common infections that are presumably associated with various types of lymphoma and specific clinical features. However, conclusive data are lacking and results from different regional studies are conflicting. Hence, a national study was performed in order to investigate potential associations between hepatitis infections and lymphoma in the Republic of Moldova. Methodology: Data were collected from newly diagnosed adult lymphoma patients from January 2020 to January 2022. Patients who were not tested for HBsAg and anti-HCV and those with an undetermined lymphoma subtype diagnosis were excluded from the study. Subjects with and without viral hepatitis were then evaluated on the basis of clinical and pathological characteristics. Results: One hundred and twenty-nine lymphoma patients were included in the study; 15 (11.6%) patients were diagnosed with hepatitis B, 21 (16.3%) patients with hepatitis C, and 1 (0.78%) patient was positive for both. The majority of hepatitis patients were over 60 years old (62.2%), presented with stage III or IV (81%), had normal lactate dehydrogenase (58.3%) and 0 or 1 extranodal sites (78.4%). The most common lymphoma subtypes were diffuse large B-cell lymphoma (64.9%) and marginal zone lymphoma (8.1%). We did not find any statistically significant differences between infected and uninfected lymphoma patients in regards to clinical features, specific lymphoma subtypes, and presence and location of extranodal involvement. Conclusions: Presence of hepatitis B or C virus infections is not associated with specific clinical and pathological features in Moldovan lymphoma patients.

Le bien-être global des patients atteints de lymphomes non hodgkiniensIntroduction. Le lymphome non hodgkinien (LNH) est une tumeur lymphoïde ayant un impact sur la santé physique, psychologique, le spirituel bien-être, l'intégration sociale, la relation vie-maladie étant ainsi multidimensionnelle. L'objectif de l'étude était d'évaluer le bien-être global des patients atteints de LNH. Materiel et méthodes. L'étude descriptive de 116 patients adultes (65 femmes, 51 hommes) atteints de LNH a été menée. L'entretien individuel a été réalisé suite à une enquête de bien-être épidémiologique, clinique et psychologique (GWB). Résultats. La moyenne du score GWB était plus faible chez les patients du groupe d'âge 18-40 ans (score moyen 43,75), était plus élevée chez les hommes (62,2, détresse modérée), ce qui exprime moins de stress psycho-émotionnel par rapport aux femmes (54,5, sévère détresse). Les patients atteints d'un LNH agressif ont rapporté un score GWB significativement plus faible (p = 0,003). La maladie extra ganglionnaire (p = 0,15)

Background: Non-Hodgkin’s lymphomas (NHL) are malignant tumors that develop from lymphoid tissue. Primary lymph node (LN) involvement is the most common localization (52-70%). The integration of Rituximab (R) in the NHL treatment represented a turning point. The aim of this study was to evaluate the therapeutic impact of the use of R in combination with conventional polychemotherapeutic (PChT) in the treatment of nodal onset NHL. Material and methods: A descriptive cohort study was performed on 80 patients diagnosed with NHL. Results: In the study participated: men – 39(48.8%), women – 41(51.2%). The mean age of the patients was 56.09 ± 13.6 years. The onset of NHL occurred in peripheral l/n in 85.0% of cases, in mediastinal LN – 7.5%, and abdominals in 7.5%. Stages I-II were identified in 21(26.2%) patients, stages III-IV in 59(73.8%) cases. Aggressive NHLs were diagnosed in 54(67.5%) patients, indolent NHLs in 26(32.5%) cases. In 61(76.3%) patients, first-line R+PChT treatment was applied – group 1(G1), and in 19(23.8%) cases conventional PChT was applied – group 2(G2). The overall response rate (ORR) in G1 was 86.8%, in G2 – 63.1%. Complete remissions (CR) were obtained in G1 in 63.9% of patients, in G2 – 47.3% of cases. Progression-free survival (PFS) in G1 had a median of 20 months, and in G2 the median was 12 months (p <0.05). Conclusions: The use of Rituximab increased the ORR rate (86.8% vs 63.1%), the frequency of CR (63.9% vs 47.3%) and PFS (20 months vs 12 months (p <0.05).

Non-Hodgkin’s lymphoma (NHL) presents a group of histologically and biologically inhomogeneous B and T cell neoplasms of lymphoid tissue with a completely unidentified etiology. Antiphospholipid antibodies (aPL) are antibodies produced as a result of misinterpretation of platelet membrane phospholipids. It is well known that antiphospholipid antibodies are general risk factors that induce the disorder of the physiological process of hemostasis. Respectively, it is interesting to appreciate the incidence of antiphospholipid antibodies in new non-Hodgkin lymphomas patients depending on age, sex, type of non-Hodgkin’s lymphoma, the peculiarities of the onset of the disease, the degree of disease spread. According to the results of our study, we found a 14.8% incidence of aPL in primary patients with non-Hodgkin’s lymphoma, more frequently in men and people older than 50 years. The positivity of aPL antibodies depended on the immunohistochemical type of malignant lymphoma, the degree of dissemination of the tumor process and independent of the location of the tumor focus (nodal or extranodal) of NHL. The incidence of aPL antibody types was uneven with the obvious predominance of lupus anticoagulant. Th is study allowed the evaluation of the incidence of antiphospholipid antibodies in primary patients with non-Hodgkin’s lymphoma.